Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARADOR: Sacubitril/Valsartan vs Enalapril on Endothelial Function
NCT03119623Phase 4Withdrawn
- Sponsor
- Brigham and Women's Hospital
- Start
- Jun 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF), sponsored by Brigham and Women's Hospital. Planned start Jun 2017; status: withdrawn.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT03119623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03119623.